Follow-The-Filings

Security · featured owners

TEVA Teva Pharmaceutical Inds Ltd

Health Care SPONSORED ADS Equity as of 2026 Q2 among managers we track

  • 8 Owners
  • #169
  • Max 4.0%
  • Master 0.03%
  • $435M
  • 2 add 6 reduce

TEVA (Teva Pharmaceutical Inds Ltd) is held in 8 featured 13F books as of 2026 Q2. Harry Burn - Sound Shore Management is the largest tracked holder by portfolio weight (4.0%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 4.0% (Harry Burn - Sound Shore Management) · not free-float ownership

  1. Harry Burn Reduce 4.0%
  2. Glenview Capital Management Reduce 3.1%
  3. David Einhorn Reduce 2.5%
  4. David Witzke Reduce 1.1%
  5. Stanley Druckenmiller Reduce 0.41%
  6. Cathie Wood Add 0.02%

Holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

History
Glenview Capital Management 2026 Q2 3.1% Reduce −23.7% 5,081,091 $172M History
Harry Burn - Sound Shore Management 2026 Q2 4.0% Reduce −2.1% 3,804,497 $129M History
David Einhorn - DME Capital Management 2026 Q2 2.5% Reduce −0.8% 2,886,059 $98M History
Stanley Druckenmiller - Duquesne Family Office 2026 Q2 0.41% Reduce −73.7% 624,999 $21M History
David Witzke - Avidity Partners Management 2026 Q2 1.1% Reduce −55.6% 200,000 $7M History
Ron Baron - Bamco Inc. (Baron Capital) 2026 Q2 0.01% Add +6.9% 138,987 $5M History
Cathie Wood - Ark Investment Management 2026 Q2 0.02% Add +0.5% 68,653 $2M History
Farallon Capital Management 2026 Q2 0.01% Reduce −88.7% 40,000 $1M History

8 current · options excluded

SEC filings

Recent issuer filings from EDGAR · 10 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 1.01,2.03,9.01 Filing Doc
8-K 8.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
424B5 Filing Doc
424B5 Filing Doc
8-K 3.03,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.07 Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 11 rows shown

Filed Form Detail Links
4 Period Sep 19, 2026 Filing Doc
4 Period Sep 18, 2026 Filing Doc
4 Period Aug 21, 2026 · 2 forms Filing Doc
4 Period Aug 17, 2026 Filing Doc
4 Period Aug 5, 2026 Filing Doc
4 Period Aug 3, 2026 · 2 forms Filing Doc
4 Period Jun 18, 2026 Filing Doc
4 Period Jun 11, 2026 Filing Doc
4 Period Jun 5, 2026 · 10 forms Filing Doc
4 Period Jun 3, 2026 Filing Doc
4 Period May 28, 2026 · 4 forms Filing Doc

Updated 7 days ago Source: SEC EDGAR submissions All on EDGAR

Financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $15.85B $16.54B $17.26B
Gross profit $7.64B $8.06B $8.94B
Gross margin * 48.2% 48.7% 51.8%
Net income -$0.559B -$1.64B $1.41B
Net margin * -3.5% -9.9% 8.2%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $12.48B $12.55B $13.95B
Total non-current assets * $30.98B $26.77B $26.8B
Total assets $43.46B $39.33B $40.75B
Total current liabilities $12.25B $12.8B $13.46B
Total non-current liabilities $24.55B $20.81B $19.38B
Total equity $7.51B $5.37B $7.91B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $1.37B $1.25B $1.65B
Cash from investing $968M $792M $737M
Cash from financing -$1.91B -$1.79B -$2.15B
Net change in cash $393M $74M $256M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

Ownership over time

filing count by report period · click a bar for that quarter’s holders